Craft

ZAI Lab

Stock Price

$16.1

2024-04-29

Market Capitalization

$1.6 B

2024-04-29

Revenue

$266.7 M

FY, 2023

ZAI Lab Summary

Company Summary

Overview
Zai Lab is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for cancer, autoimmune and infectious diseases. It offers Zejula, a selective small-molecule poly (ADP-ribose) PARP 1/2inhibitor; Optune, a portable device that delivers tumor treating fields; and Qinlock, a switch-control tyrosine kinase inhibitor.
Type
Public
Status
Active
Founded
2014
HQ
CN | view all locations
Website
http://www.zailaboratory.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Samantha Du

    Samantha Du, Founder, Chair and Chief Executive Officer

  • Harald Reinhart

    Harald Reinhart, Chief Medical Officer, Autoimmune and Infectious Diseases

  • Billy Cho

    Billy Cho, Chief Financial Officer

  • F. Ty Edmondson

    F. Ty Edmondson, Chief Legal Officer

LocationsView all

7 locations detected

  • Shang Hai Shi HQ

    China

    Jin Ke Lu, Pu Dong Xin Qu

  • Cambridge, MA

    United States

    314 Main St 4th 100

  • Menlo Park, CA

    United States

    1440 O'Brien Dr ste a & c

  • Suzhou, Jiangsu Sheng

    China

    Building 7&8 Biobay 218 Sangtian Street Suzhou

  • Bei Jing Shi

    China

    Xi Da Wang Lu, Chao Yang Qu

  • Hong Kong, Hong Kong Island

    Hong Kong

    Room 2301 , 23/F. Island Place Tower 510 King 's Road

and 1 others

ZAI Lab Financials

Summary Financials

Revenue (Q1, 2024)
$87.1M
Gross profit (Q1, 2024)
$53.5M
Net income (Q1, 2024)
($53.5M)
Cash (FY, 2023)
$790.2M
EBIT (Q1, 2024)
($70.3M)
Enterprise value
$1.1B

Footer menu